公开(公告)号：EP3122373A1

公开(公告)日：2017-02-01

申请号：EP15713704.3

申请日：2015-03-27

申请人： FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V.

发明人： BOES, Alexander ,  SPIEGEL, Holger ,  EDGÜ, Güven ,  BEISS, Veronique ,  SACK, Markus ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： A61K39/00 ,  C07K14/445

CPC分类号： A61K39/015 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/445 ,  C07K16/205 ,  C07K2319/00 ,  C07K2319/21 ,  G01N33/56905 ,  G01N2333/445 ,  Y02A50/412

摘要： The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

摘要翻译： 本公开涉及由不同重组蛋白组成的新型疟疾疫苗，特别是包含来自红血球前，血液和性寄生虫阶段的几种不同的恶性疟原虫抗原的重组融合蛋白。 蛋白质和/或融合蛋白将用于混合物疫苗制剂中以在人体中引发保护性免疫应答。 编码所述重组蛋白质的核酸分子，载体，含有核酸的宿主细胞以及用于制备和产生此类蛋白质的方法; 通过使用所述疟疾疫苗或编码所述蛋白质和/或融合蛋白的所述核酸分子诱导或产生的抗体以及使用这种抗体或重组衍生物进行被动免疫治疗。

公开(公告)号：EP2988776B1

公开(公告)日：2018-12-26

申请号：EP14719741.2

申请日：2014-04-24

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

发明人： BOES, Alexander ,  SPIEGEL, Holger ,  GÜVEN, Edgü ,  BEISS, Veronique ,  SACK, Markus ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： A61K39/002 ,  A61K39/015 ,  C12N15/62

CPC分类号： C07K14/445 ,  A61K39/002 ,  A61K39/015 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  Y02A50/412

摘要： The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

公开(公告)号：EP3374384A1

公开(公告)日：2018-09-19

申请号：EP16794592.2

申请日：2016-11-09

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. ,  Rheinisch-Westfälische Technische Hochschule Aachen

发明人： EDGÜ, Güven ,  SACK, Markus ,  BEISS, Veronique ,  BOES, Alexander ,  SPIEGEL, Holger ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： C07K14/705 ,  C07K16/00 ,  C07K16/20 ,  C07K14/445

CPC分类号： A61K39/002 ,  A61K39/29 ,  A61K2039/505 ,  C07K14/445 ,  C07K16/1045 ,  C07K16/1081 ,  C07K16/205 ,  C07K19/00 ,  C07K2319/00 ,  C07K2319/30 ,  Y02A50/383 ,  Y02A50/392 ,  Y02A50/41 ,  Y02A50/412

摘要： The technology provided herein relates to a novel type of recombinant protein complexes, in particular of antibody-like recombinant fusion protein complexes, hereinafter referred to as immunoassemblins (IAs), suitable as animal and human vaccines comprising a plurality of antigens or antigen domains derived from proteins preferably, but not necessarily presented on the surface of a pathogen. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins and protein complexes; antibodies induced or generated by the use of said vaccines or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

公开(公告)号：EP3191122A1

公开(公告)日：2017-07-19

申请号：EP15759742.8

申请日：2015-09-02

申请人： Fraunhofer Gesellschaft zur Förderung der angewandten Forschung E.V.

发明人： SPIEGEL, Holger ,  BOES, Alexander ,  EDGÜ, Güven ,  BEISS, Veronique ,  SACK, Markus ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： A61K39/015 ,  C12N15/62 ,  A61K39/00

CPC分类号： A61K39/015 ,  A61K2039/575 ,  A61K2039/64 ,  A61K2039/70 ,  C07K14/445 ,  C07K16/205 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  Y02A50/412

摘要： The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

摘要翻译： 本文提供的技术涉及由不同重组蛋白质组成的新型疟疾疫苗，特别是包含来自红细胞前期，血液和性寄生虫主要阶段的几种不同疟原虫恶性疟原虫抗原的重组融合蛋白。 蛋白质可用于混合疫苗制剂中以在人体内引发保护性免疫应答。 还公开了编码所述重组蛋白质的核酸分子，含有该核酸的载体和宿主细胞，以及制备和生产这些蛋白质的方法，以及使用所述疟疾疫苗诱导或产生的抗体，以及使用这些抗体或重组体 被动免疫治疗的衍生物。

公开(公告)号：EP2988776A1

公开(公告)日：2016-03-02

申请号：EP14719741.2

申请日：2014-04-24

申请人： Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

发明人： BOES, Alexander ,  SPIEGEL, Holger ,  GÜVEN, Edgü ,  BEISS, Veronique ,  SACK, Markus ,  REIMANN, Andreas ,  FISCHER, Rainer

IPC分类号： A61K39/002 ,  A61K39/015 ,  C12N15/62

CPC分类号： C07K14/445 ,  A61K39/002 ,  A61K39/015 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/62 ,  Y02A50/412

摘要： The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

摘要翻译： 本文提供的技术通常涉及适用于针对Apicomplexa门的寄生虫或病原体的人和/或动物疫苗的新型融合蛋白。 特别地，本公开内容涉及新颖的融合蛋白作为针对疟原虫寄生虫的疫苗的基础，包括恶性疟原虫，间日疟原虫，马鞭草，疟原虫和know know属。 编码所述融合蛋白的核酸分子，载体，含有核酸的宿主细胞和用于制备和产生此类融合蛋白的方法; 通过使用所述融合蛋白或编码所述融合蛋白的所述核酸分子诱导或产生的抗体以及所述抗体或重组衍生物用于被动免疫治疗的用途; 生产这种融合蛋白的方法; 用于预防和治疗疟疾的这种融合蛋白的组合物和方法也包括在本公开中。